Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

Trial Details

NCT ID
NCT07531095
Phase
PHASE1
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ZL-1310
  • Tarlatamab
  • Durvalumab
Locations (sample)
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • Tampa, Florida, United States|27.94752,-82.45843
  • Zion, Illinois, United States|42.44613,-87.83285
  • Saint Paul, Minnesota, United States|44.94441,-93.09327
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
  • Participants with Histologically or cytologically confirmed SCLC:
  • For Part 1, participants must have SCLC that has progressed or recurred following at least 1 line of platinum-based anti-cancer therapy.
  • For Parts 1 and 2, participants must have progressed or recurred following at least 1 line of platinum-based therapy. No prior tarlatamab is allowe…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →